MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 100040 | Name: Altretamine
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Altretamine is a synthetic cytotoxic s-triazine derivative similar in structure to alkylating agent triethylenemelamin with antineoplastic activity. Although the precise mechanism by which altretamine exerts its cytotoxic effect is unknown, N-demethylation of altretamine may produce reactive intermediates which covalently bind to DNA, resulting in DNA damage. Check for active clinical trials or closed clinical trials using this agent.

Chemical Structure

Altretamine
CAS#645-05-6 (free base)

Theoretical Analysis

MedKoo Cat#: 100040

Name: Altretamine

CAS#: 645-05-6 (free base)

Chemical Formula: C9H18N6

Exact Mass: 210.1593

Molecular Weight: 210.28

Elemental Analysis: C, 51.41; H, 8.63; N, 39.97

Price and Availability

Size Price Availability Quantity
100mg USD 250.00 2 Weeks
250mg USD 450.00 2 Weeks
500mg USD 750.00 2 Weeks
1g USD 1,250.00 2 Weeks
2g USD 2,050.00 2 Weeks
5g USD 3,650.00 2 Weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
2975-00-0 (HCl) 645-05-6 (free base)
Synonym
Hemel; Hexaloids. US brand names: Hexalen; hexamethylmelamine. Foreign brand names: Hexastat; Hexinawas; Abbreviations: HMM; HXM. Code names: ENT50852; RB1515; WR95704.
IUPAC/Chemical Name
N2,N2,N4,N4,N6,N6-hexamethyl-1,3,5-triazine-2,4,6-triamine
InChi Key
UUVWYPNAQBNQJQ-UHFFFAOYSA-N
InChi Code
InChI=1S/C9H18N6/c1-13(2)7-10-8(14(3)4)12-9(11-7)15(5)6/h1-6H3
SMILES Code
CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1
Appearance
White to off-white solid powder.
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Altretamine is a synthetic cytotoxic s-triazine derivative similar in structure to alkylating agent triethylenemelamin with antineoplastic activity. Although the precise mechanism by which altretamine exerts its cytotoxic effect is unknown, N-demethylation of altretamine may produce reactive intermediates which covalently bind to DNA, resulting in DNA damage. Altretamine  was approved by the FDA in 1990.   DRUG DESCRIPTION HEXALEN® (altretamine) capsules, is a synthetic cytotoxic antineoplastic s-triazine derivative. HEXALEN® capsules contain 50 mg of altretamine for oral administration. Inert ingredients include lactose, anhydrous and calcium stearate. Altretamine, known chemically as N,N,N',N',N“,N”-hexamethyl-1,3,5-triazine-2,4,6-triamine. Its empirical formula is C9H18N6 with a molecular weight of 210.28. Altretamine is a white crystalline powder, melting at 172°± 1°C. Altretamine is practically insoluble in water but is increasingly soluble at pH 3 and below.   CLINICAL PHARMACOLOGY The precise mechanism by which HEXALEN® capsules exerts its cytotoxic effect is unknown, although a number of theoretical possibilities have been studied. Structurally, HEXALEN® capsules resembles the alkylating agent triethylenemelamine, yet in vitro tests for alkylating activity of HEXALEN® capsules and its metabolites have been negative. HEXALEN® capsules has been demonstrated to be efficacious for certain ovarian tumors resistant to classical alkylating agents. Metabolism of altretamine is a requirement for cytotoxicity. Synthetic monohydroxymethylmelamines, and products of altretamine metabolism, in vitro and in vivo, can form covalent adducts with tissue macromolecules including DNA, but the relevance of these reactions to antitumor activity is unknown. HEXALEN® capsules is well-absorbed following oral administration in humans, but undergoes rapid and extensive demethylation in the liver, producing variation in altretamine plasma levels. The principal metabolites are pentamethylmelamine and tetramethylmelamine. Pharmacokinetic studies were performed in a limited number of patients and should be considered preliminary. After oral administration of HEXALEN® capsules to 11 patients with advanced ovarian cancer in doses of 120-300 mg/m², peak plasma levels (as measured by gas-chromatographic assay) were reached between 0.5 and 3 hours, varying from 0.2 to 20.8 mg/l. Half-life of the β-phase of elimination ranged from 4.7 to 10.2 hours. Altretamine and metabolites show binding to plasma proteins. The free fractions of altretamine, pentamethylmelamine and tetramethylmelamine are 6%, 25% and 50%, respectively. Following oral administration of 14C-ring-labeled altretamine (4 mg/kg), urinary recovery of radioactivity was 61% at 24 hours and 90% at 72 hours. Human urinary metabolites were Ndemethylated homologues of altretamine with <1% unmetabolized altretamine excreted at 24 hours. After intraperitoneal administration of 14C-ring-labeled altretamine to mice, tissue distribution was rapid in all organs, reaching a maximum at 30 minutes. The excretory organs (liver and kidney) and the small intestine showed high concentrations of radioactivity, whereas relatively low concentrations were found in other organs, including the brain. There have been no formal pharmacokinetic studies in patients with compromised hepatic and/or renal function, though HEXALEN® capsules has been administered both concurrently and following nephrotoxic drugs such as cisplatin. HEXALEN® capsules has been administered in 4 divided doses, with meals and at bedtime, though there is no pharmacokinetic data on this schedule nor information from formal interaction studies about the effect of food on its bioavailability or pharmacokinetics. In two studies in patients with persistent or recurrent ovarian cancer following first-line treatment with cisplatin and/or alkylating agent-based combinations, HEXALEN® capsules was administered as a single agent for 14 or 21 days of a 28 day cycle. In the 51 patients with measurable or evaluable disease, there were 6 clinical complete responses, 1 pathologic complete response, and 2 partial responses for an overall response rate of 18%. The duration of these responses ranged from 2 months in a patient with a palpable pelvic mass to 36 months in a patient who achieved a pathologic complete response. In some patients, tumor regression was associated with improvement in symptoms and performance status.    

Preparing Stock Solutions

The following data is based on the product molecular weight 210.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Altretamine. 2016 Mar 1. PMID: 31643842. 2: Hansen LA, Hughes TE. Altretamine. DICP. 1991 Feb;25(2):146-52. doi: 10.1177/106002809102500209. PMID: 1905441. 3: Lee CR, Faulds D. Altretamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cancer chemotherapy. Drugs. 1995 Jun;49(6):932-53. doi: 10.2165/00003495-199549060-00007. PMID: 7641606. 4: Damia G, D'Incalci M. Clinical pharmacokinetics of altretamine. Clin Pharmacokinet. 1995 Jun;28(6):439-48. doi: 10.2165/00003088-199528060-00002. PMID: 7656502. 5: Young RC. Hexamethylmelamine (altretamine): early National Cancer Institute trials. Cancer Treat Rev. 1991 Mar;18 Suppl A:31-5. doi: 10.1016/0305-7372(91)90022-r. PMID: 1904307. 6: Comis RL. Hexamethylmelamine (altretamine) in small cell lung cancer (SCLC). Cancer Treat Rev. 1991 Mar;18 Suppl A:85-90. doi: 10.1016/0305-7372(91)90028-x. PMID: 1646071. 7: Goswami S, Ghosh R, Prasanthan P, Kishore N. Mode of interaction of altretamine with calf thymus DNA: biophysical insights. J Biomol Struct Dyn. 2023 Jun;41(9):3728-3740. doi: 10.1080/07391102.2022.2054472. Epub 2022 Mar 28. PMID: 35343872. 8: Ghosh R, Bharathkar SK, Kishore N. Anticancer altretamine recognition by bovine serum albumin and its role as inhibitor of fibril formation: Biophysical insights. Int J Biol Macromol. 2019 Oct 1;138:359-369. doi: 10.1016/j.ijbiomac.2019.07.093. Epub 2019 Jul 16. PMID: 31323265. 9: Keldsen N, Havsteen H, Vergote I, Bertelsen K, Jakobsen A. Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study. Gynecol Oncol. 2003 Feb;88(2):118-22. doi: 10.1016/s0090-8258(02)00103-8. PMID: 12586589. 10: Markman M, Blessing JA, Moore D, Ball H, Lentz SS. Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 1998 Jun;69(3):226-9. doi: 10.1006/gyno.1998.5016. PMID: 9648592. 11: Chan JK, Loizzi V, Manetta A, Berman ML. Oral altretamine used as salvage therapy in recurrent ovarian cancer. Gynecol Oncol. 2004 Jan;92(1):368-71. doi: 10.1016/j.ygyno.2003.09.017. PMID: 14751188. 12: Gidwani B, Vyas A. Pharmacokinetic study of solid-lipid-nanoparticles of altretamine complexed epichlorohydrin-β-cyclodextrin for enhanced solubility and oral bioavailability. Int J Biol Macromol. 2017 Aug;101:24-31. doi: 10.1016/j.ijbiomac.2017.03.047. Epub 2017 Mar 14. PMID: 28315435. 13: Alghazwani Y, Venkatesan K, Prabahar K, El-Sherbiny M, Elsherbiny N, Qushawy M. The Combined Anti-Tumor Efficacy of Bioactive Hydroxyapatite Nanoparticles Loaded with Altretamine. Pharmaceutics. 2023 Jan 16;15(1):302. doi: 10.3390/pharmaceutics15010302. PMID: 36678930; PMCID: PMC9861632. 14: Wharton JT. Hexamethylmelamine (altretamine) activity as a single agent in previously untreated advanced ovarian cancer. Cancer Treat Rev. 1991 Mar;18 Suppl A:15-21. doi: 10.1016/0305-7372(91)90020-z. PMID: 1904304. 15: Olver I, Davy M, Lüftner D, Park SH, Egorin M, Ellis A, Webster L. A phase I study of paclitaxel and altretamine as second-line therapy to cisplatin regimens for ovarian cancer. Cancer Chemother Pharmacol. 2001 Aug;48(2):109-14. doi: 10.1007/s002800000263. PMID: 11561776. 16: Gidwani B, Vyas A. Preparation, characterization, and optimization of altretamine-loaded solid lipid nanoparticles using Box-Behnken design and response surface methodology. Artif Cells Nanomed Biotechnol. 2016;44(2):571-80. doi: 10.3109/21691401.2014.971462. Epub 2014 Nov 3. PMID: 25363752. 17: Zon RT, McClean J, Helman D, Ansari R, Picus J, Sandler A, Williams SD, Loehrer PJ Sr. Altretamine for the treatment of metastatic renal cell carcinoma. A Hoosier Oncology Group trial. Invest New Drugs. 2001;19(3):229-31. doi: 10.1023/a:1010620601431. PMID: 11561679. 18: Malik IA. Altretamine is an effective palliative therapy of patients with recurrent epithelial ovarian cancer. Jpn J Clin Oncol. 2001 Feb;31(2):69-73. doi: 10.1093/jjco/hye012. PMID: 11302345. 19: Runhaar EA, Neijt JP, Holthuis JJ, de Vos D. The bioavailability of three altretamine formulations. Pharm Weekbl Sci. 1989 Dec 15;11(6):218-23. doi: 10.1007/BF01959414. PMID: 2515524. 20: Altretamine for ovarian cancer. Med Lett Drugs Ther. 1991 Aug 9;33(850):76-7. PMID: 1712892.